Core Points - Healthcare Triangle, Inc. (HCTI) has entered into warrant exercise agreements with accredited and institutional investors to exercise existing warrants for a total of 239,051 shares of common stock, generating approximately $478,000 in gross cash proceeds [1][2] - The existing warrants' exercise price has been reduced from $20.92 to $2.00 per share, and the new warrants will have an exercise price of $3.00 per share, with a five-year expiration from the date of issuance [1][2] Financial Details - The gross proceeds from the warrant inducement are expected to be around $478,000, excluding any potential proceeds from the exercise of the new warrants and before deducting financial advisor fees and other expenses [2] - The closing of the offering is anticipated to occur on or about October 8, 2025, subject to customary closing conditions [2]

Core Insights - WallachBeth Capital LLC announced that Healthcare Triangle, Inc. has entered into warrant exercise agreements with accredited and institutional investors [1] Company Summary - Healthcare Triangle, Inc. is recognized as a leader in digital transformation solutions for the healthcare and life sciences sectors [1] - The company has agreed to exercise outstanding warrants to purchase a total of 377,702 shares of its common stock [1]

Core Insights - Healthcare Triangle, Inc. has entered into warrant exercise agreements with three accredited investors to exercise existing warrants for a total of 812,775 shares of common stock, generating approximately $1.63 million in gross cash proceeds [1][2] - The existing warrants' exercise price has been reduced from $20.92 to $2.00 per share, and the new warrants will have an exercise price of $3.00 per share, with a total of 812,775 shares available for purchase [1] - The transaction is expected to close on October 2, 2025, subject to customary closing conditions [2] Financial Details - The gross proceeds from the warrant inducement are expected to be around $1.63 million, excluding potential proceeds from the exercise of the new warrants and before deducting placement agent fees and other expenses [2] - The new warrants will be exercisable upon stockholder approval and will expire five years from the date of such approval [1] Company Background - WallachBeth Capital LLC is acting as the sole placement agent for this warrant inducement transaction, providing capital markets and institutional execution services [2][4]

Company Overview - bioAffinity Technologies, Inc. is a biotechnology company focused on developing noninvasive tests for early-stage cancer detection [1] - The company has announced a public offering of securities to raise capital [1] Offering Details - The offering consists of 1,921,799 shares of Common Stock priced at $2.50 per share, or pre-funded warrants at $2.493 each [2] - Each pre-funded warrant is immediately exercisable for one share of Common Stock and will expire when fully exercised [2] - The closing of the offering is expected to occur on or about September 30, 2025, pending customary closing conditions [3] Financial Aspects - The aggregate gross proceeds from the offering are expected to be significant, although the exact amount is not specified in the provided text [1] - WallachBeth Capital, LLC is acting as the sole placement agent for this offering [3]

Core Viewpoint - bioAffinity Technologies, Inc. has successfully closed a best efforts offering of securities, raising a total of $3.25 million before expenses [1]. Group 1: Offering Details - The offering included 10,156,250 shares of Common Stock and warrants to purchase up to 15,234,375 shares of Common Stock, with a combined public offering price of $0.32 per share or pre-funded warrant [2]. - WallachBeth Capital, LLC served as the sole placement agent for this offering [2]. Group 2: Company Background - WallachBeth Capital LLC provides a wide range of capital markets and investment banking services, particularly to the healthcare sector, facilitating connections between corporate clients and leading institutions [5].